Skip to content

DEVELOPMENT pipeline

Oncology

SOLID TUMORS

Compound / MOA
Project
Therapeutic area
Phase
Vorasidenib
S95032
Low grade Glioma with IDH 1/2 mutation
DPC
1
2
3
Ivosidenib
S95031
Solid tumors (new indication)
DPC
1
2
3
Anti-MET
S95027
Non small Cell Lung Cancer
DPC
1
2
3
Vorasidenib + pembrolizumab
S95032
Grade 2-3 glioma with IDH1/2 mutation
DPC
1/2
3
Ivosidenib combo
S95031
Solid tumors (new indication)
DPC
1/2
3
Anti-TIM3 combo
S95018
Solid tumors
DPC
1/2
3
Anti-CD73 combo
S95024
Solid tumors
DPC
1/2
3
Anti-PD-L1/4-1BB
S95012
Solid tumors
DPC
1/2
3
Anti-NKG2A combo
S95029
Solid tumors
DPC
1/2
3
MAT2A inhibitor
S95035
Solid tumors
DPC
1/2
3
ND
S95043
Solid tumors
DPC
1
2
3

HEMATOLOGICAL MALIGNANCIES

Compound / MOA
Project
Therapeutic area
Phase
Ivosidenib + 7+3 (chimio)
S95031
Hematological malignancies (new indication)
DPC
1
2
3
Calaspargase pegol combo
S95015
Hematological malignancies (new indication)
DPC
1
2
3
BCL-2 inhibitor + azacitidine
S65487
1st line Acute Myeloid Leukemia (AML)
DPC
1/2
3
ND
S227928
Hematological malignancies
DPC
1
2
3

Neuroscience

Compound / MOA
Project
Therapeutic area
Phase
LRRK2 inhibitor
S221237
Parkinson’s Disease
DPC
1
2
3
ND
S230815
Neurodevelopmental disorder
DPC
1
2
3

Immuno-inflammation

Compound / MOA
Project
Therapeutic area
Phase
ND
S95041
Autoimmune disease
DPC
1
2
3
ND
S95042
Autoimmune disease
DPC
1
2
3

PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, ND= Not disclosed